Shrink Nanotechnologies, a company into developing medical diagnostics and sensors, has entered into a technology integration and development agreement with Lydall. The collaboration seeks to produce effective and low cost single molecule detection sensors for infectious diseases and environmental hazards using Shrink’s NanoPetal Nanostructure Technology.
Under the terms of the agreement, Lydall will provide Shrink with certain quantities of its Solupore thermoplastic membrane for the purpose of conducting a one-year research and development project.
Shrink and Lydall said that the goal of the project is to develop a ultra-rapid diagnostic platform that increases the sensitivity of fluorescent-based assays by integrating Solupore technology with Shrink’s rapid prototyping system, ShrinkChip Manufacturing System and NanoPetal technology.
As per the terms of the agreement, any ownership of new intellectual property will be based on inventorship.
Mark Baum, CEO of Shrink Nanotechnologies, said: “The new relationship with Lydall is part of our effort to turn our NanoShrink materials into viable systems used in critical point-of-care and point-of-operations products. The market for the types of sensors is in the billions of US Dollars in annual sales, and they are used in a wide range of commercial applications such as food safety, personalised drug therapies and disease screening, to name a few.
“By producing more of the overall system solution, with the integration of the Lydall Solupore material, we seek to increase the flexibility and scope of the important diagnostic devices and in turn open the door to future strategic partnerships with leading research laboratories in industry and academia.”